Therapy News and Research

RSS

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Sanofi and Regeneron Pharmaceuticals, Inc. announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment.

21 Jul 2012

uniQure receives positive recommendation from EMA CHMP for Glybera

uniQure announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion that recommends marketing authorization of Glybera (alipogene tiparvovec) as a treatment for lipoprotein lipase deficiency (LPLD) under exceptional circumstances.

21 Jul 2012

Onyx receives FDA approval for Kyprolis to treat multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that its partner, Onyx Pharmaceuticals, Inc., received U.S. Food and Drug Administration (FDA) approval for Kyprolis (carfilzomib) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Velcade (bortezomib) for Injection and an immunomodulatory agent, such as Thalomid (thalidomide) or Revlimid (lenalidomide), and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Montefiore physician to develop tablet computer app for children with cochlear implants

Elena Willis, MD Resident Physician, Department of Otorhinolaryngology - Head and Neck Surgery, Montefiore Medical Center, has been awarded a $10,000 Resident Research Grant by The American Academy of Otolaryngology - Head and Neck Surgery, sponsored by The Oticon Foundation, to develop a tablet computer app to help improve the speech of children with cochlear implants.

20 Jul 2012

CPAP benefits extend to mild OSA patients

The use of continuous positive airway pressure treatment, an effective option for severe obstructive sleep apnea, should be extended to sleepy patients with milder OSA, say US researchers.

20 Jul 2012

Poststroke speech therapy ‘should be reorganized’

Results of the randomized ACT NoW trial show no benefit of “enhanced” over “everyday” communication therapy for patients with dysarthria resulting from stroke.

20 Jul 2012

Study on relationship between pain and higher brain functions

University of Texas Medical Branch at Galveston professor Volker Neugebauer has been awarded a four-year, $1.36 million grant by the National Institute of Neurological Disorders and Stroke to conduct an innovative study of the relationship between pain and parts of the brain associated with cognitive thought and emotional response.

20 Jul 2012

American leadership on HIV/AIDS making a difference in U.S. and abroad

"As two people who worked as physicians in the early years of the HIV/AIDS epidemic before the miracle of antiretroviral drug (ARV) therapy, and who now have the honor of leading the domestic and global HIV/AIDS programs for the Obama administration, we look back in awe of the American leadership that has transformed the epidemic in the 22 years since the International AIDS Conference was last held on U.S. soil," Grant Colfax, director of the Office of National AIDS Policy, and U.S. Global AIDS Coordinator Ambassador Eric Goosby write in a Washington Blade opinion piece.

20 Jul 2012

Natural compound can virtually eradicate HIV in infected culture cells

A new study by scientists on the Florida campus of The Scripps Research Institute shows, in cell culture, a natural compound can virtually eliminate human immunodeficiency virus (HIV) in infected cells. The compound defines a novel class of HIV anti-viral drugs endowed with the capacity to repress viral replication in acutely and chronically infected cells.

20 Jul 2012

Silymarin does not offer significant improvements for patients with HCV

Silymarin, an extract of milk thistle commonly used to treat chronic liver disease by millions of people around the World, does not offer significant improvements for patients, according to a new study conducted by a nationwide group of researchers including faculty at the Perelman School of Medicine at the University of Pennsylvania.

20 Jul 2012

UNAIDS releases report highlighting gains, gaps in global HIV/AIDS response

Ahead of the XIX International AIDS Conference next week, UNAIDS on Wednesday launched a new report, titled "Together we will end AIDS", "that shows that a record eight million people are now receiving antiretroviral therapy [ARVs], and that domestic funding for HIV has exceeded global investments," the U.N. News Centre reports.

20 Jul 2012

HIV in MSM increasing in countries of all incomes

A new Lancet Series published to coincide with the AIDS2012 meeting highlights a population where the HIV epidemic is growing in countries of all incomes: men who have sex with men (MSM). The first paper in the Series charts the epidemiology of HIV among MSM, and is by Professor Chris Beyrer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, and colleagues.

20 Jul 2012

New blood sugar monitor: An interview with Sherita Hill Golden

Type 1 diabetes is a disorder in which the body makes proteins (antibodies) against the cells in the pancreas that produce insulin, destroying those cells. As a result, individuals are unable to secrete insulin to normalize blood sugar and hyperglycemia results.

20 Jul 2012

Study demonstrates how nerve stimulation paired with specific experiences can reorganize the brain

UT Dallas researchers recently demonstrated how nerve stimulation paired with specific experiences, such as movements or sounds, can reorganize the brain. This technology could lead to new treatments for stroke, tinnitus, autism and other disorders.

20 Jul 2012

Researchers identify six genes with driving mutations in melanoma

It's been a burning question in melanoma research: Tumor cells are full of ultraviolet (UV)-induced genetic damage caused by sunlight exposure, but which mutations drive this cancer? None have been conclusively tied to melanoma. The sheer abundance of these passenger mutations has obscured the search for genetic driver mutations that actually matter in melanoma development and progression.

20 Jul 2012

CPAP effectively reduces symptoms and improves QOL in sleepy patients with milder OSA

Continuous positive airway pressure (CPAP), well established as an effective treatment for severe obstructive sleep apnea (OSA), is also effective in patients with mild and moderately severe OSA and daytime sleepiness, according to a new study.

20 Jul 2012

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

Viewpoints: Researchers see potential to control HIV pandemic; The 'ceaseless attacks' on women's reproductive health

We are at a moment of extraordinary optimism in the response to the human immunodeficiency virus (HIV). A series of scientific breakthroughs ... have the potential to markedly expand the available preventive tools. There is evidence of the first cure of an HIV-infected person. And most important, the finding that early initiation of antiretroviral therapy can both improve individual patient outcomes and reduce the risk of HIV transmission to sexual partners by 96% has led many to assert what had so long seemed impossible: that control of the HIV pandemic may be achievable.

20 Jul 2012

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

The first patient has now been enrolled into the Phase 1 clinical trial sponsored by Viral Genetics' and supported by a donation from Scott and White Foundation. The trial will study Metabolic Disruption Technology (MDT) compounds in combination with an existing cancer therapy to treat drug-resistant ovarian cancer.

20 Jul 2012